"Fibrinolytic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN.
Descriptor ID |
D005343
|
MeSH Number(s) |
D27.505.519.421.750 D27.505.954.411.320 D27.505.954.502.427
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Fibrinolytic Agents".
Below are MeSH descriptors whose meaning is more specific than "Fibrinolytic Agents".
This graph shows the total number of publications written about "Fibrinolytic Agents" by people in this website by year, and whether "Fibrinolytic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 3 | 1 | 4 |
1996 | 1 | 1 | 2 |
1997 | 2 | 2 | 4 |
1998 | 1 | 0 | 1 |
1999 | 3 | 3 | 6 |
2000 | 1 | 2 | 3 |
2001 | 3 | 3 | 6 |
2002 | 1 | 2 | 3 |
2003 | 8 | 0 | 8 |
2004 | 6 | 6 | 12 |
2005 | 5 | 2 | 7 |
2006 | 8 | 2 | 10 |
2007 | 8 | 4 | 12 |
2008 | 11 | 0 | 11 |
2009 | 6 | 5 | 11 |
2010 | 7 | 1 | 8 |
2011 | 13 | 5 | 18 |
2012 | 2 | 2 | 4 |
2013 | 13 | 3 | 16 |
2014 | 6 | 3 | 9 |
2015 | 6 | 2 | 8 |
2016 | 8 | 0 | 8 |
2017 | 7 | 4 | 11 |
2018 | 4 | 3 | 7 |
2019 | 8 | 3 | 11 |
2020 | 3 | 5 | 8 |
2021 | 5 | 4 | 9 |
2022 | 0 | 8 | 8 |
2023 | 1 | 3 | 4 |
2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fibrinolytic Agents" by people in Profiles.
-
Outcomes of Pleural Space Infections in Patients With Indwelling Pleural Catheters for Active Malignancies. J Bronchology Interv Pulmonol. 2024 Apr 01; 31(2):155-159.
-
Comparing Low- or Standard-Dose Alteplase in Endovascular Thrombectomy: Insights From a Nationwide Registry. Stroke. 2024 Mar; 55(3):532-540.
-
Apixaban for Prevention of Thromboembolism in Pediatric Heart?Disease. J Am Coll Cardiol. 2023 12 12; 82(24):2296-2309.
-
Strokes Averted by Intravenous Thrombolysis: A Secondary Analysis of a Prospective, Multicenter, Controlled Trial of Mobile Stroke Units. Ann Neurol. 2024 Feb; 95(2):347-361.
-
Development and Validation of a Novel 1-year Mortality Risk Score That Includes the Use of Antithrombotic in Patients With Overt Gastrointestinal Bleeding. J Clin Gastroenterol. 2023 08 01; 57(7):700-706.
-
Outcomes of patients with pre-existing disability managed by mobile stroke units: A sub-analysis of the BEST-MSU study. Int J Stroke. 2023 Dec; 18(10):1209-1218.
-
Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study. Diabetes Obes Metab. 2023 06; 25(6):1750-1757.
-
Direct oral to parenteral anticoagulant transitions: Role of factor Xa inhibitor-specific anti-Xa concentrations. Pharmacotherapy. 2022 10; 42(10):768-779.
-
Thrombolysis Experience in Costa Rica Compared Against Individual Patient Data from two Randomized Controlled Trials. J Stroke Cerebrovasc Dis. 2022 Aug; 31(8):106599.
-
Bleeding Risk With Combination Intrapleural Fibrinolytic and Enzyme Therapy in Pleural Infection: An International, Multicenter, Retrospective Cohort Study. Chest. 2022 Dec; 162(6):1384-1392.